Fagron NV Total Assets
Fagron NV total assets. Based on the latest financial reports, Fagron NV (FAGR) holds total assets worth €1.53 Billion EUR (≈ $1.78 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Fagron NV worth for the company's overall valuation and market capitalisation.
Total Assets of Fagron NV (2004–2025)
Total assets of Fagron NV from 2004 to 2025. This chart illustrates how Fagron NV's total assets have evolved over time, based on quarterly financial data. See FAGR stock price and chart for real-time trading data and today's change.
Fagron NV - Asset Composition Analysis
Fagron NV Total Assets Breakdown (December 2025)
Fagron NV total assets breakdown as of December 2025. Fagron NV's total assets of €1.53 Billion consist of 37.2% current assets and 62.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 14.9% |
| Accounts Receivable | €95.24 Million | 7.7% |
| Inventory | €158.91 Million | 12.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €99.67 Million | 8.0% |
| Goodwill | €471.10 Million | 37.9% |
Asset Composition Trend (2004–2025)
This chart illustrates how Fagron NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Fagron NV current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fagron NV's current assets represent 37.2% of total assets in 2025, a decrease from 44.2% in 2004.
- Cash Position: Cash and equivalents constituted 14.9% of total assets in 2025, up from 1.9% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 45.0% of total assets, an increase from 21.0% in 2004.
- Asset Diversification: The largest asset category is goodwill at 37.9% of total assets.
Fagron NV Competitors by Total Assets
Key competitors of Fagron NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Fagron NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.77 | 1.76 | 1.43 |
| Quick Ratio | 1.02 | 1.06 | 0.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €216.19 Million | €161.21 Million | €75.36 Million |
Fagron NV - Advanced Valuation Insights
This section examines the relationship between Fagron NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.64 |
| Latest Market Cap to Assets Ratio | 1.25 |
| Asset Growth Rate (YoY) | 14.7% |
| Total Assets | €1.24 Billion |
| Market Capitalization | $1.55 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Fagron NV's assets above their book value (1.25x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Fagron NV's assets grew by 14.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Fagron NV (2004–2025)
The table below shows the annual total assets of Fagron NV from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.24 Billion ≈ $1.45 Billion |
+14.73% |
| 2024-12-31 | €1.08 Billion ≈ $1.27 Billion |
+7.60% |
| 2023-12-31 | €1.01 Billion ≈ $1.18 Billion |
+3.70% |
| 2022-12-31 | €971.01 Million ≈ $1.14 Billion |
+21.31% |
| 2021-12-31 | €800.42 Million ≈ $935.78 Million |
+6.32% |
| 2020-12-31 | €752.83 Million ≈ $880.13 Million |
-6.04% |
| 2019-12-31 | €801.24 Million ≈ $936.73 Million |
+17.35% |
| 2018-12-31 | €682.77 Million ≈ $798.23 Million |
+14.94% |
| 2017-12-31 | €594.05 Million ≈ $694.50 Million |
-31.57% |
| 2016-12-31 | €868.05 Million ≈ $1.01 Billion |
+25.92% |
| 2015-12-31 | €689.38 Million ≈ $805.96 Million |
-29.20% |
| 2014-12-31 | €973.75 Million ≈ $1.14 Billion |
+21.01% |
| 2013-12-31 | €804.69 Million ≈ $940.77 Million |
+7.45% |
| 2012-12-31 | €748.89 Million ≈ $875.54 Million |
+10.09% |
| 2011-12-31 | €680.23 Million ≈ $795.26 Million |
+18.59% |
| 2010-12-31 | €573.59 Million ≈ $670.59 Million |
+21.48% |
| 2009-12-31 | €472.16 Million ≈ $552.00 Million |
+13.03% |
| 2008-12-31 | €417.73 Million ≈ $488.37 Million |
+20.22% |
| 2007-12-31 | €347.47 Million ≈ $406.23 Million |
+21.72% |
| 2006-12-31 | €285.46 Million ≈ $333.73 Million |
+4.93% |
| 2005-12-31 | €272.04 Million ≈ $318.04 Million |
-0.42% |
| 2004-12-31 | €273.19 Million ≈ $319.39 Million |
-- |
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Com… Read more